Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.59 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123765 | 1.00 | GABBR2 (0.59) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL59840 | 1.00 | GABBR2 (0.59) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| Hydrochloric Acid SCHEMBL3874351 | 0.98 | GABBR2 (0.57) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4150999 | 0.98 | GABBR2 (0.57) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL9386161 | 0.98 | GABBR2 (0.57) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| Hydrochloric Acid SCHEMBL2934796 | 0.98 | GABBR2 (0.57) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| Acetamide SCHEMBL27677566 | 0.92 | GABBR2 (0.52) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL7244087 | 0.90 | GABBR2 (0.55) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL5846637 | 0.89 | KMT2A (0.49) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL5845485 | 0.89 | KMT2A (0.49) | GABBR2GABBR1KMT2ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012477-A | Phenylalanine aminomutase and application thereof in preparation of R-type beta-amino acid | 常州合全药业有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4619046-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | Genome & Company, Inc. (KR) | 2025-09-24 | — | — | EP | claimed |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | claimed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | claimed |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | INDI MOLECULAR, INC. | 2024-05-30 | — | — | US | claimed |
| WO-2024107014-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | GENOME AND COMPANY (KR) | 2024-05-23 | — | — | WO | claimed |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | REGENERON PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | claimed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | claimed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | claimed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-2069516-B1 | SPECIFIC HYDROLYSIS OF THE N-UNPROTECTED (R) -ESTER OF (3 ) -AMIN0-3-ARYLPR0PI0NIC ACID ESTERS | REDDY S LAB EU LTD DR (GB) | 2010-12-15 | — | — | EP | claimed |
| CN-101558159-A | Specific hydrolysis of the n-unprotected (r) -ester of (3 ) -amin0-3-arylpr0pi0nic acid esters | REDDYS LAB LTD DR (GB) | 2009-10-14 | — | — | CN | claimed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | GABBR2 288/4885GABBR1 339/4885KMT2A 4240/4885 |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | ARGLU1, NGLY1, VIP | GABBR2 3602/4885GABBR1 4067/4885KMT2A 3792/4885 |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | GABBR2 3196/4885GABBR1 3247/4885KMT2A 4351/4885 |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | FCER2, FCGR2A, FCGR1A | GABBR2 2083/4885GABBR1 2799/4885KMT2A 3558/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | GABBR2 675/4885GABBR1 642/4885KMT2A 4608/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | GABBR2 937/4885GABBR1 754/4885KMT2A 3178/4885 |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | ARGLU1, NGLY1, VIP | GABBR2 3602/4885GABBR1 4067/4885KMT2A 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.